green tick

Medicines update

0 comments Read Later

Medicines update

Compound guidelines

The Pharmacy Board of Australia has released new guidelines and other tools for registered pharmacists who compound medicines.

Pharmacists who regularly compound medicines are urged to read three new policies which are due to take effect on April 28, 2015.

Those policies include the Guidelines on compounding of medicines, Background on the regulation of compounding by pharmacists, and professional practice profile for pharmacists undertaking complex compounding.

The Guidelines on compounding of medicines were subject to wide-ranging consultation and will take effect on 28 April 2015.

The guidelines have been published now so pharmacists can become familiar with their content before implementation, the Board says.

 

Antidepressant released

 

Lundbeck Australia has announce the launch of Brintellix (vortioxetine) for the treatment of

major depressive disorder (MDD) in adults including the prevention of relapse. It is the first new

antidepressant to be introduced in Australia for almost five years.

Brintellix has been studied in a clinical program that included more than 6,700 patients, of whom, more than 3,700 were treated with Brintellix.


Brintellix has shown to be efficacious in treating the symptoms of depression across a range of patient types, including those with severe depression, depressed patients with anxiety and elderly patients.

 

Cancer treatment PBS listed

Nexavar (sorafenib) has been listed on the PBS for use as second line therapy in advanced Renal Cell Carcinoma (RCC).

Nexavar has proven efficacy in second line treatment of advanced RCC after disease progression according to the Response Evaluation Criteria in Solid Tumours (RECIST) following first-line treatment with a tyrosine kinase inhibitor (TKI), vascular endothelial growth factor plus interferon, cytokines or temsirolimus.

Patients who have progressive disease defined by RECIST following first-line treatment with a TKI or who have developed intolerance to a first-line TKI of a severity necessitating permanent treatment withdrawal, are also eligible to receive PBS subsidised Nexavar


 

 Subscribe to our Newsletter


 Breaking news and special features
 A daily must-read for pharmacists
 Delivered to your inbox
By filling in your email address and clicking submit with this option selected, you agree to receive email communications from us relevant to the healthcare industry. You always have the option of unsubscribing later via an unsubscribe link or your subscriptions management page. View our privacy policy here.

Your profile is
0% complete


 
 

Pharmacy News on Twitter

­

My list
  •  
Read Later